BAY2927088_formulation B_2

Preclinical

BAY2927088_formulation B_2 is one of 7 therapeutic programs targeting Advanced Non-Small Cell Lung Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced Non-Small Cell Lung CancerRecruiting

Advanced Non-Small Cell Lung CancerPreclinical

Recruiting

Competition

Competitive Landscape

11 competitors in Advanced Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

2 2

PF-08634404

Pfizer

Phase 3

1 3

Fabhalta

Regeneron

Preclinical

1 4

Libtayo

Regeneron

Preclinical

1 5

Krazati

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 6

Bay2927088_formulation a

Bayer

Preclinical

1 7

BAY2927088_formulation B_2

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Advanced Non-Small Cell Lung Cancer

NCT05099172

Clinical

Trials by Indication[1]

Advanced Non-Small Cell Lung Cancer1 trial

An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

Recruiting· Bayer logo

Bayer·Preclinical·NCT05099172·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BAY2927088_formulation B_2. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for BAY2927088_formulation B_2. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Bayer

BAY2927088_formulation B_2

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Advanced Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News